دورية أكاديمية
أعرض في EDS

Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk.

التفاصيل البيبلوغرافية
العنوان: Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk.
المؤلفون: Chen J; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Liu S; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Ruan Z; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Wang K; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Sino-French Research Center for Life Sciences and Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: kankanwang@shsmu.edu.cn., Xi X; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: xixiaodong@shsmu.edu.cn., Mao J; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: jianhuamao@shsmu.edu.cn.
المصدر: Blood reviews [Blood Rev] 2024 Sep; Vol. 67, pp. 101220. Date of Electronic Publication: 2024 Jun 07.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 8708558 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1681 (Electronic) Linking ISSN: 0268960X NLM ISO Abbreviation: Blood Rev Subsets: MEDLINE
أسماء مطبوعة: Publication: 2001- : London : Elsevier
Original Publication: [Edinburgh ; New York] : Churchill Livingstone, [c1987-
مواضيع طبية MeSH: Thrombosis*/etiology , Thrombosis*/prevention & control , Hemorrhage*/etiology , Hemorrhage*/prevention & control , Hemorrhage*/chemically induced , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/therapeutic use , Fibrinolytic Agents*/therapeutic use , Fibrinolytic Agents*/adverse effects , Neoplasms*/drug therapy , Neoplasms*/complications, Humans ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Aggregation Inhibitors/adverse effects ; Animals
مستخلص: Although immunotherapy is expanding treatment options for cancer patients, the prognosis of advanced cancer remains poor, and these patients must contend with both cancers and cancer-related thrombotic events. In particular, immune checkpoint inhibitors are associated with an increased risk of atherosclerotic thrombotic events. Given the fundamental role of platelets in atherothrombosis, co-administration of antiplatelet agents is always indicated. Platelets are also involved in all steps of cancer progression. Classical antithrombotic drugs can cause inevitable hemorrhagic side effects due to blocking integrin β3 bidirectional signaling, which regulates simultaneously thrombosis and hemostasis. Meanwhile, many promising new targets are emerging with minimal bleeding risk and desirable anti-tumor effects. This review will focus on the issue of thrombosis during immune checkpoint inhibitor treatment and the role of platelet activation in cancer progression as well as explore the mechanisms by which novel antiplatelet therapies may exert both antithrombotic and antitumor effects without excessive bleeding risk.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023. Published by Elsevier Ltd.)
فهرسة مساهمة: Keywords: Antithrombotic therapy; Atherothrombosis; Cancer; Immune checkpoint inhibitors; Platelet activation
المشرفين على المادة: 0 (Immune Checkpoint Inhibitors)
0 (Fibrinolytic Agents)
0 (Platelet Aggregation Inhibitors)
تواريخ الأحداث: Date Created: 20240614 Date Completed: 20240825 Latest Revision: 20240825
رمز التحديث: 20240826
DOI: 10.1016/j.blre.2024.101220
PMID: 38876840
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1681
DOI:10.1016/j.blre.2024.101220